Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cangene Consolidates R&D Operations | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cangene Consolidates R&D Operations

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cangene Corp. is consolidating its R&D activities within the Winnipeg head office location. The company recently instituted several strategic changes in its R&D processes to formalize and enhance new product development. Having a consolidated group is part of the company’s efforts to help strengthen the links between research, product development and manufacturing activities, and increase operational effectiveness.

A large portion of the activities in Cangene’s Mississauga R&D operation related to a contract research project with the Apotex Group, is now concluded and to two products (Accretropin and Leucotropin) have been submitted for licensure. Ongoing responsibility for any additional development of these two products will be transferred to the Winnipeg group.

The reorganization includes a reduction of 4% of the staff and an expected operating savings of approximately $1.5 million annually.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics